|
Coll RC, Schroder K, Pelegrin P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022 Aug;43(8):653-668. doi: 10.1016/j.tips.2022.04.003. Epub 2022 May 3. PubMed PMID: 35513901.
AÑO: 2022; IF: 13.8
|
35513901
|
Angosto-Bazarra D, Alarcon-Vila C, Hurtado-Navarro L, Banos MC, Rivers-Auty J, Pelegrin P. Evolutionary analyses of the gasdermin family suggest conserved roles in infection response despite loss of pore-forming functionality. BMC Biol. 2022 Jan 7;20(1):9. doi: 10.1186/s12915-021-01220-z. PubMed PMID: 34996441; PubMed Central PMCID: PMC8742441.
AÑO: 2022; IF: 7.364
|
|
Beamer E, Morgan J, Alves M, Menendez Mendez A, Morris G, Zimmer B, Conte G, de Diego-Garcia L, Alarcon-Vila C, Yiu Ng NK, Madden S, Calzaferri F, de Los Rios C, Garcia AG, Hamacher M, Dinkel K, Pelegrin P, Henshall DC, Nicke A, Engel T. Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice. Br J Pharmacol. 2022 Jun;179(12):2986-3006. doi: 10.1111/bph.15785. Epub 2022 Feb 4. PubMed PMID: 34962289.
AÑO: 2022; IF: 7.3
|
|
Adriouch S, Pelegrin P. ASC nanobodies to counteract the consequences of inflammasome activation. EMBO Mol Med. 2022 Jun 8;14(6):e16087. doi: 10.15252/emmm.202216087. Epub 2022 May 16. PubMed PMID: 35574976; PubMed Central PMCID: PMC9174878.
AÑO: 2022; IF: 11.1
|
|
Hurtado-Navarro L, Baroja-Mazo A, Martinez-Banaclocha H, Pelegrin P. Assessment of ASC Oligomerization by Flow Cytometry. Methods Mol Biol. 2022;2459:1-9. doi: 10.1007/978-1-0716-2144-8_1. PubMed PMID: 35212949.
AÑO: 2022
|